Scarica l'app Stockscreener
252.38
1.16%
-2.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$255.35
Aprire:
$254.78
Volume 24 ore:
722.04K
Relative Volume:
0.71
Capitalizzazione di mercato:
$36.84B
Reddito:
$5.26B
Utile/perdita netta:
$1.44B
Rapporto P/E:
25.83
EPS:
9.7713
Flusso di cassa netto:
$1.76B
1 W Prestazione:
-2.02%
1M Prestazione:
+3.18%
6M Prestazione:
-7.68%
1 anno Prestazione:
+1.41%
Intervallo 1D:
$250.19
$255.62
Intervallo di 1 settimana:
$250.19
$264.09
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
252.38 | 37.27B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
523.99 | 186.40B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
201.79 | 58.70B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.29 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.00 | 38.25B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
ResMed Inc.'s (NYSE:RMD) Stock Has Fared Decently: Is the Market Following Strong Financials? - Yahoo Finance
Wealth Enhancement Advisory Services LLC Raises Stake in ResMed Inc. $RMD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 6,991 Shares of ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Vest Financial LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) to Release Earnings on Thursday - MarketBeat
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.
Allstate Corp Invests $1.45 Million in ResMed Inc. $RMD - MarketBeat
ResMed Shares Garner Bullish Sentiment on Analyst Backing and Regulatory Milestone - AD HOC NEWS
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
Vaughan David Investments LLC IL Sells 4,092 Shares of ResMed Inc. $RMD - MarketBeat
Is ResMed (NYSE:RMD) A Risky Investment? - 富途资讯
QRG Capital Management Inc. Sells 63,696 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc (NYSE:RMD) S&P 500 Chart Maps Long-Term Medical Presence - Kalkine Media
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ResMed Inc.: How a Sleep-Tech Quiet Giant Became a Data-Driven Respiratory Powerhouse - AD HOC NEWS
Harel Insurance Investments & Financial Services Ltd. Lowers Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stephens Investment Management Group LLC Has $78.02 Million Stock Position in ResMed Inc. $RMD - MarketBeat
The Truth About ResMed Inc.: Sleep Tech Stock That Quietly Went Beast Mode - AD HOC NEWS
ResMed Inc. $RMD Shares Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Should ResMed's (RMD) Earnings Beat and Margin Gains Require Action From Investors? - Yahoo Finance
ResMed Inc. (NYSE:RMD) Embodies Quality Investing Principles - Chartmill
Earnings Beat and Cash Flow Strength Could Be A Game Changer For ResMed (RMD) - Sahm
A Look At ResMed (RMD) Valuation After Earnings Beat And Strong Start To Fiscal 2026 - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Sleep Care Tailwinds? - Yahoo Finance
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today - sharewise.com
Resmed promotes new chief strategy officer from within - MassDevice
Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD) - Barchart.com
Shorts Report: Can ResMed Inc maintain sales growthWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Nordea Investment Management AB Acquires 26,629 Shares of ResMed Inc. $RMD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Buys 4,222 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - sharewise.com
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
ResMed Inc. Announces Change in Board Leadership - MSN
ResMed Chairman Emeritus Peter Farrell Sells 2,000 Shares Under Trading Plan - TipRanks
ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
ResMed updates CDI and share structure for December 2025 - MSN
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Yahoo Finance
Bogart Wealth LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Aug PostEarnings: What dividend growth rate does ResMed Inc offerJuly 2025 Gainers & Real-Time Buy Signal Notifications - baoquankhu1.vn
What you need to know ahead of ResMed's earnings release - MSN
Zacks Research Comments on ResMed's Q2 Earnings (NYSE:RMD) - MarketBeat
The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
How ResMed Inc. stock performs in easing cyclesIndex Update & Reliable Intraday Trade Alerts - ulpravda.ru
Resmed Insider Sold Shares Worth $497,660, According to a Recent SEC Filing - marketscreener.com
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com UK
Resmed director Farrell sells $497k in shares - Investing.com
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):